Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stangel

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Journal of Neuroimmunology|May 18, 2000
Normal polyclonal immunoglobulins ('IVIg') inhibit microglial phagocytosis in vitroM Stangel, E Joly, N J Scolding, et al.
Der Nervenarzt|June 8, 2018
[Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017]O Aktas, M P Wattjes, M Stangel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 10, 2008
CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesionsC Trebst, F König, Rm Ransohoff, et al.
Current Neuropharmacology|September 2, 2009
Fumaric Acid and its esters: an emerging treatment for multiple sclerosisD Moharregh-Khiabani, R A Linker, R Gold, et al.
European Journal of Neurology|November 23, 2006
Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulinsC Trebst, K Brunhorn, M Lindner, et al.
Der Nervenarzt|January 23, 2008
[Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects]M Stangel, D Moharregh-Khiabani, R A Linker, et al.
Der Nervenarzt|January 14, 2009
[The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies]M Stangel, H-P Hartung, R Gold, et al.
Immunological Investigations|August 1, 1997
Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitroM Stangel, H C Schumacher, K Ruprecht, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 22, 1999
Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosisM Stangel, F Boegner, C H Klatt, et al.
Neuropathology and Applied Neurobiology|March 4, 2011
Lack of cuprizone-induced demyelination in the murine spinal cord despite oligodendroglial alterations substantiates the concept of site-specific susceptibilities of the central nervous systemV Herder, F Hansmann, M Stangel, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Journal of Neuroimmunology|May 18, 2000
Normal polyclonal immunoglobulins ('IVIg') inhibit microglial phagocytosis in vitroM Stangel, E Joly, N J Scolding, et al.
Der Nervenarzt|June 8, 2018
[Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017]O Aktas, M P Wattjes, M Stangel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 10, 2008
CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesionsC Trebst, F König, Rm Ransohoff, et al.
Current Neuropharmacology|September 2, 2009
Fumaric Acid and its esters: an emerging treatment for multiple sclerosisD Moharregh-Khiabani, R A Linker, R Gold, et al.
European Journal of Neurology|November 23, 2006
Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulinsC Trebst, K Brunhorn, M Lindner, et al.
Der Nervenarzt|January 23, 2008
[Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects]M Stangel, D Moharregh-Khiabani, R A Linker, et al.
Der Nervenarzt|January 14, 2009
[The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies]M Stangel, H-P Hartung, R Gold, et al.
Immunological Investigations|August 1, 1997
Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitroM Stangel, H C Schumacher, K Ruprecht, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 22, 1999
Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosisM Stangel, F Boegner, C H Klatt, et al.
Neuropathology and Applied Neurobiology|March 4, 2011
Lack of cuprizone-induced demyelination in the murine spinal cord despite oligodendroglial alterations substantiates the concept of site-specific susceptibilities of the central nervous systemV Herder, F Hansmann, M Stangel, et al.
Pageof 7